Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma

Biomark Med. 2018 Mar;12(3):245-256. doi: 10.2217/bmm-2017-0273. Epub 2018 Feb 14.

Abstract

Aim: We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation.

Patients & methods: Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control.

Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor.

Conclusion: Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients.

Keywords: ATG-4B; bioinformatics; biomarkers; hepatocellular carcinoma; miR-661; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Autophagy-Related Proteins / genetics*
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology
  • Case-Control Studies
  • Cysteine Endopeptidases / genetics*
  • Female
  • Humans
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology
  • Male
  • MicroRNAs / blood*
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • RNA, Messenger / blood*
  • ROC Curve
  • Up-Regulation

Substances

  • Autophagy-Related Proteins
  • Biomarkers, Tumor
  • MIRN661 microRNA, human
  • MicroRNAs
  • RNA, Messenger
  • ATG4B protein, human
  • Cysteine Endopeptidases